Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon
about
Interferon beta for secondary progressive multiple sclerosisClinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets.Imaging of multiple sclerosis: role in neurotherapeutics.Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve.Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?Multiple sclerosis lesions: insights from imaging techniques.Neuroimaging in multiple sclerosis: neurotherapeutic implications.Current perspectives on interferon Beta-1b for the treatment of multiple sclerosisInternational consensus statement on the use of disease-modifying agents in multiple sclerosis.The emerging role of MRI in multiple sclerosis and the new diagnostic criteria.Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrationsA longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosisDevelopment and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction.Interferon-beta1a treatment for multiple sclerosis.Current and future therapies for multiple sclerosis.Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis.MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.Immunotherapy of multiple sclerosis: the state of the art.Magnetic resonance image registration in multiple sclerosis: comparison with repositioning error and observer-based variability.Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms.[Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?Does MRI lesion activity regress in secondary progressive multiple sclerosis?Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis.The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND studyMosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonistsMosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists
P2860
Q24203879-342CCC29-DFCD-450D-9E9A-E00AECBAFE54Q30640097-2682C04F-5E37-4134-813C-5EC35B37843FQ30989935-1A36AB9A-3726-4514-AEEA-C27B3D3A01D3Q31117157-AEB17ADE-D027-4728-8A3D-614E491C4C71Q33289264-9C9C06D0-E8E6-4937-BB91-8E1E4B6F9F8CQ33505423-1843E89D-C256-44F2-95BB-0C684847EC79Q33806032-42981D65-45C3-492A-BC44-C9587EF382F3Q34253488-C20E1B2D-DF5A-40B9-A405-4E951C3FB2FCQ34590270-52EE3D34-C138-4F4C-8F37-78F5DA7D7605Q34590306-41F3C1A0-893F-4084-BBDE-BFA6D67AE77AQ35456727-1BF31DE9-A7BF-4ACA-B23F-C47838574D32Q35462222-3BA6B5DF-B7F9-4C14-9844-FCDA085AD431Q35667191-8D6D8BC7-FE3F-4CBC-813B-3D0417F51017Q36106748-8A4BEB78-7593-4A91-B32D-0255DC78363CQ37287769-80283296-9075-4ECD-9CD1-FCA7C47A75D1Q37386441-C8C0D558-2EC9-4838-95CD-53C12D01A0D5Q37964985-A8AB51D6-71DA-47AE-8E93-6A1899E3FFA8Q38083041-A982647C-8C14-4A80-A252-CA9A6D0EA978Q40641900-9640EBBF-7071-4697-9B08-0DCB247A49A3Q44554579-50AAF7AC-D17B-491D-BBA7-1E00F900332EQ44762856-356D8184-719B-47FA-B067-4B0EE62AE4C7Q45155454-BE8C7C48-3A54-4DB3-AA1B-497780C2F0E1Q46912034-BEF07ACE-1CFF-4734-9BD4-CDF7CA22DF8DQ48301343-43FCE420-4AB0-46B8-827B-9E16DBA4B7BDQ48618954-CC3CF4CC-BCD3-4F87-AF29-3EA60A12FA9BQ52072205-BF6F45DF-EBD5-4348-9DF7-303EBB280073Q57911735-D005E269-C1B1-4662-B3C1-D38DA23063E7Q58125463-57327B25-8129-49CF-B629-695FCBDDC6B2Q58149673-2F59A939-020E-4E02-959A-498B84360997
P2860
Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Effect of interferon-beta1b on ...... on Interferon-beta1b in secon
@en
Effect of interferon-beta1b on ...... on Interferon-beta1b in secon
@nl
type
label
Effect of interferon-beta1b on ...... on Interferon-beta1b in secon
@en
Effect of interferon-beta1b on ...... on Interferon-beta1b in secon
@nl
prefLabel
Effect of interferon-beta1b on ...... on Interferon-beta1b in secon
@en
Effect of interferon-beta1b on ...... on Interferon-beta1b in secon
@nl
P2093
P2860
P921
P1433
P1476
Effect of interferon-beta1b on ...... on Interferon-beta1b in secon
@en
P2093
D G MacManus
D H Miller
I F Moseley
P D Molyneux
P2860
P304
P356
10.1002/1531-8249(199912)46:6<850::AID-ANA7>3.0.CO;2-Q
P577
1999-12-01T00:00:00Z